Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Vitrolife AB ( (SE:VITR) ).
Vitrolife reported 2025 full-year sales of SEK 3.44 billion, down 5% in Swedish kronor but up 2% in local currencies, with organic growth of 4% excluding discontinued EMEA activities, driven mainly by solid demand for consumables and steady performance in technologies and genetics. Despite resilient underlying operations, margins contracted and reported earnings were heavily hit by a SEK 5.36 billion goodwill impairment linked to a restructuring of Genetic Services and SEK 55 million in restructuring costs, pushing net income deeply negative for both the fourth quarter and the full year, although adjusted profit and cash flow remained positive; the board nevertheless maintained its dividend proposal at SEK 1.10 per share, signalling confidence in the company’s cash generation and long-term prospects.
The most recent analyst rating on (SE:VITR) stock is a Buy with a SEK129.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.
More about Vitrolife AB
Vitrolife AB is a Sweden-based medical technology group listed on Nasdaq Stockholm that develops and sells products and technologies for assisted reproduction, with key product groups in consumables, technologies and genetics serving fertility clinics across EMEA, the Americas and APAC.
Average Trading Volume: 197,134
Technical Sentiment Signal: Sell
Current Market Cap: SEK15.74B
For a thorough assessment of VITR stock, go to TipRanks’ Stock Analysis page.